ANI Pharmaceuticals
ANIP
About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Employees: 897
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
57% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $874K
20% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 74
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
1% more funds holding
Funds holding: 227 [Q1] → 229 (+2) [Q2]
0.82% less ownership
Funds ownership: 91.84% [Q1] → 91.02% (-0.82%) [Q2]
5% less capital invested
Capital invested by funds: $1.35B [Q1] → $1.28B (-$63.5M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 2 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Guggenheim
Vamil Divan
|
$114
|
Buy
Maintained
|
8 Sep 2025 |
|
Truist Securities
Gregory Fraser
|
$77
|
Hold
Maintained
|
11 Aug 2025 |
|
HC Wainwright & Co.
Brandon Folkes
|
$93
|
Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 7 articles about ANIP published over the past 30 days
